公开(公告)号：EP0738280A1

公开(公告)日：1996-10-23

申请号：EP95909489.0

申请日：1995-02-06

申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES ,  RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. ,  YEDA RESEARCH & DEVELOPMENT COMPANY, LTD. ,  MOODY, Terry W.

发明人： MOODY, Terry, W. ,  GOZES, Illana ,  BRENNEMAN, Douglas, E. ,  FRIDKIN, Matityahu

IPC分类号： A61K38 ,  A61P9 ,  A61P35 ,  A61P43 ,  C07K7 ,  C07K14

CPC分类号： C07K7/083 ,  A61K38/00 ,  C07K14/57563

摘要： The present invention relates to a family of peptides encoding antagonists of the vasoactive intestinal peptide (VIP) of formula (I) designed to distinguish multiple receptors that mediate VIP neurotransmission, neurotrophism and cell division. The invention also relates to methods of using these peptides to antagonize VIP-associated activity and function. The invention further relates to pharmaceutical compositions designed to inhibit VIP-associated activity. In formula (I), R?1 and R2¿ are members independently selected from the group consisting of hydrogen, C¿1? to C20 alkyl and C1 to C20 acyl, provided that at least one of R?1 or R2¿ is hydrogen; and X?1 and X2¿ are members independently selected from the group consisting of naturally occurring amino acids and amino acid mimetics.

公开(公告)号：EP0738280B1

公开(公告)日：2001-02-14

申请号：EP95909489.7

申请日：1995-02-06

申请人： THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES ,  RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. ,  YEDA RESEARCH & DEVELOPMENT COMPANY, LTD. ,  MOODY, Terry W.

发明人： MOODY, Terry, W. ,  GOZES, Illana ,  BRENNEMAN, Douglas, E. ,  FRIDKIN, Matityahu

IPC分类号： C07K14/575 ,  C07K7/08 ,  A61K38/22 ,  A61K38/10

CPC分类号： C07K7/083 ,  A61K38/00 ,  C07K14/57563

摘要： The present invention relates to a family of peptides encoding antagonists of the vasoactive intestinal peptide (VIP) of formula (I) designed to distinguish multiple receptors that mediate VIP neurotransmission, neurotrophism and cell division. The invention also relates to methods of using these peptides to antagonize VIP-associated activity and function. The invention further relates to pharmaceutical compositions designed to inhibit VIP-associated activity. In formula (I), R and R are members independently selected from the group consisting of hydrogen, C1 to C20 alkyl and C1 to C20 acyl, provided that at least one of R or R is hydrogen; and X and X are members independently selected from the group consisting of naturally occurring amino acids and amino acid mimetics.